NCT05225584
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors treatment 1 recruiting NCT02689453
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) treatment 1 completed NCT02314247
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma treatment 2 terminated NCT02594267
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) treatment 1 completed NCT00299351
A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. No drug interventions treatment 2 unknown_status NCT04696705
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients No drug interventions treatment 0 unknown_status NCT02953652
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) treatment 2 completed NCT00972842
Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) treatment 1 / 2 terminated NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT00985140
Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides No drug interventions Not Available Not Available terminated NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment Not Available Not Available completed NCT03493451
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms treatment 2 completed NCT03240211
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL treatment 1 recruiting NCT05967949
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. Not Available Not Available recruiting NCT04747236
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL treatment 2 recruiting NCT02757248
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL treatment 1 withdrawn NCT06492629
Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma treatment 2 active_not_recruiting NCT04705090
A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma No drug interventions treatment 2 unknown_status NCT05238064
Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL treatment 1 / 2 not_yet_recruiting NCT03884205
GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL No drug interventions Not Available Not Available unknown_status NCT03900442
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort treatment 1 unknown_status NCT03922724
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma No drug interventions treatment 2 recruiting NCT00374699
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas treatment 1 / 2 completed NCT02520219
Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study treatment 2 unknown_status NCT00453427
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas treatment 1 / 2 completed NCT00704691
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas treatment 0 terminated NCT05105412
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas treatment 1 / 2 terminated NCT04767308
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies treatment 0 unknown_status NCT02223208
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas treatment 1 / 2 active_not_recruiting NCT05377827
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies treatment 1 active_not_recruiting NCT06120504
A Safety Study of SGN-35T in Adults With Advanced Cancers No drug interventions treatment 1 recruiting NCT06422247
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy No drug interventions Not Available Not Available recruiting NCT06561048
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma treatment 3 recruiting NCT06630091
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study treatment 2 not_yet_recruiting NCT04045470
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma No drug interventions diagnostic Not Available recruiting NCT06072131
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL treatment 3 recruiting NCT04569032
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression treatment 2 active_not_recruiting NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available active_not_recruiting NCT06176690
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas No drug interventions treatment 1 not_yet_recruiting NCT06254495
A Safety Study of SGN-35C in Adults With Advanced Cancers No drug interventions treatment 1 recruiting NCT04668690
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL treatment 3 not_yet_recruiting NCT01846390
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma treatment 1 completed NCT04489264
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma No drug interventions Not Available Not Available recruiting NCT01748721
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma treatment 1 completed NCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) Not Available Not Available not_yet_recruiting NCT01796002
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma treatment 3 completed NCT03921879
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma No drug interventions treatment 1 unknown_status NCT00337987
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma treatment 2 completed NCT01116154
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma treatment 1 terminated NCT00646854
Alemtuzumab and CHOP in T-cell Lymphoma treatment 3 completed NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer treatment 1 / 2 completed NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy treatment 1 completed NCT05321147
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 treatment 1 completed NCT06548347
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma treatment 2 / 3 not_yet_recruiting NCT02535247
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT05963347
Go-CHOP as the Frontline Therapy for PTCL treatment 2 recruiting NCT00791947
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT treatment 2 completed NCT03079947
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients No drug interventions Not Available Not Available unknown_status NCT01258998
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma No drug interventions treatment 2 completed NCT01169298
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma treatment 1 completed NCT03719105
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma treatment 0 recruiting NCT00930605
The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) treatment 2 completed NCT00101205
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma treatment 1 terminated NCT03927105
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma treatment 2 completed NCT01614197
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma treatment 1 completed NCT01355783
A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma treatment 3 withdrawn NCT05441761
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL treatment 1 / 2 recruiting NCT03302728
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma treatment 1 completed NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma treatment 1 completed NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma treatment 2 completed NCT00481871
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies treatment 1 / 2 completed NCT02676778
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma treatment 2 completed NCT04254107
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer treatment 1 terminated NCT02567656
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma No drug interventions treatment 1 completed NCT00933985
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia treatment 1 terminated NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors treatment 1 / 2 terminated NCT02495415
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas treatment 2 unknown_status NCT00131937
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma treatment 2 completed NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas treatment 1 / 2 terminated NCT03553537
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma treatment 3 unknown_status NCT01806337
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma treatment 2 completed NCT04984837
Study of Lacutamab in Peripheral T-cell Lymphoma treatment 2 recruiting NCT00118352
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT04548700
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL treatment 1 terminated NCT01664975
Treatment of Peripheral T-cell Lymphoma treatment 4 completed NCT04425070
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma treatment 1 / 2 active_not_recruiting NCT01036399
Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients treatment 2 terminated NCT04480099
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT06151106
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma treatment 2 recruiting NCT05883449
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL treatment 2 recruiting NCT05749549
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers No drug interventions treatment 1 / 2 active_not_recruiting NCT06550336
A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). treatment 2 active_not_recruiting NCT05675813
Genotype-guided Treatment in Newly Diagnosed PTCL treatment 1 / 2 recruiting NCT02181218
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas treatment 1 completed NCT05958719
Chidamide Plus Azacitidine for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma treatment 2 recruiting NCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders treatment 1 terminated NCT04444141
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma treatment 1 / 2 terminated NCT01155817
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease treatment 1 completed NCT04512534
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma treatment 2 recruiting NCT04526834
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma No drug interventions treatment 1 active_not_recruiting NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT02232516
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma treatment 2 active_not_recruiting NCT03023358
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients treatment 3 unknown_status NCT03999658
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies treatment 2 withdrawn NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant treatment 1 / 2 completed NCT05138458
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL No drug interventions treatment 1 / 2 suspended NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies treatment Not Available completed NCT01822886
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients treatment 2 completed NCT01456039
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) treatment 1 / 2 completed NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies No drug interventions treatment Not Available terminated NCT03071822
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas treatment 4 unknown_status NCT00441025
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL treatment 2 terminated NCT04480125
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy treatment 2 unknown_status NCT04457830
The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). No drug interventions treatment 2 unknown_status NCT01401530
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma treatment 1 completed NCT06421948
Linperlisib Combined With Chidamide in Patients With PTCL treatment 1 / 2 recruiting NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) treatment 1 active_not_recruiting NCT04234048
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT01470066
Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas No drug interventions Not Available Not Available unknown_status NCT01767766
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT02364466
Cohort of Peripheral T Cell Lymphoma No drug interventions Not Available Not Available unknown_status NCT00136565
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma treatment 2 completed NCT04828174
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies No drug interventions treatment 1 suspended NCT01336920
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma treatment 1 completed NCT01689220
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea treatment 1 completed NCT02809573
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients treatment 1 completed NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT00888927
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma treatment 1 / 2 completed NCT01679860
Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma treatment 2 completed NCT04040491
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma treatment 4 unknown_status NCT03964480
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. No drug interventions Not Available Not Available recruiting NCT03502629
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) treatment 2 unknown_status NCT05979792
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma No drug interventions treatment 0 not_yet_recruiting NCT05949944
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma treatment 1 / 2 recruiting NCT04028440
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 0 unknown_status NCT05269940
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 / 2 unknown_status NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer treatment 2 completed NCT00891072
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 completed NCT04061772
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma treatment 2 unknown_status NCT03355768
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL other 3 withdrawn NCT03051568
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma No drug interventions diagnostic Not Available unknown_status NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT06511869
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) treatment 2 active_not_recruiting NCT00865969
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma treatment 2 completed NCT04880746
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study treatment 3 recruiting NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies treatment 2 completed NCT05444712
Transplantation After Complete Response In Patients With T-cell Lymphoma No drug interventions health_services_research Not Available recruiting NCT05239910
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL treatment 2 withdrawn NCT03051581
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma No drug interventions diagnostic Not Available unknown_status NCT06511895
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) treatment 2 recruiting NCT03553914
PLM60 for Peripheral T Cell Lymphoma (PTCL) No drug interventions treatment 1 / 2 withdrawn NCT03947255
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma treatment 2 terminated NCT01523223
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies treatment 1 completed NCT05559008
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes treatment 1 / 2 recruiting NCT02753543
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma treatment 2 unknown_status NCT01678443
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies treatment 1 terminated NCT01408043
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma treatment Not Available terminated NCT03141203
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients treatment 1 / 2 completed NCT03321890
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) treatment 2 unknown_status NCT05934864
Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST) No drug interventions Not Available Not Available recruiting NCT05006664
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL treatment 2 not_yet_recruiting NCT00426764
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma treatment 2 completed NCT01841021
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 treatment Not Available terminated NCT03742921
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma Not Available Not Available completed NCT01075321
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma treatment 1 / 2 completed NCT03150602
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy treatment 4 unknown_status NCT01420679
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients treatment 3 terminated NCT01336933
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma treatment 2 completed NCT01110733
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry No drug interventions Not Available Not Available completed NCT00274651
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas treatment 2 terminated NCT01644253
Phase 1b Safety and Efficacy Study of TRU-016 treatment 1 terminated NCT01959477
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant treatment 0 completed NCT01261247
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma treatment 2 completed NCT05137847
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) Not Available Not Available completed NCT06509945
Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL No drug interventions treatment Not Available recruiting NCT00007345
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma treatment 2 completed NCT02362997
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL treatment 2 completed NCT02856997
Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma treatment 2 unknown_status NCT04068597
Study to Evaluate CCS1477 in Haematological Malignancies treatment 1 / 2 recruiting NCT03297697
Minimal Residual Disease in Peripheral T-cell Lymphoma No drug interventions Not Available Not Available completed NCT02512497
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation treatment 1 unknown_status NCT01839097
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) treatment 1 completed NCT01769911
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma treatment Not Available withdrawn NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer treatment Not Available completed NCT02404571
GDP in Frontline Chemotherapy for Patients With PTCL-NOS No drug interventions treatment 2 unknown_status NCT04213209
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" Not Available Not Available completed NCT00705809
T-Cell Project: Epidemiologic Component No drug interventions Not Available Not Available completed NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies treatment 1 / 2 completed NCT00970385
Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma No drug interventions treatment 3 completed NCT00211185
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma treatment 2 completed NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT04390737
Evaluate the Safety and Clinical Activity of HH2853 No drug interventions treatment 1 / 2 recruiting NCT03212937
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma treatment 1 completed NCT03547700
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) treatment 1 / 2 active_not_recruiting NCT05495100
A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma treatment 2 unknown_status NCT04052659
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL treatment 2 not_yet_recruiting NCT01611142
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) treatment 2 completed NCT03586999
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas treatment 1 / 2 active_not_recruiting NCT06173999
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma No drug interventions treatment 1 / 2 recruiting NCT01716806
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) treatment 2 completed NCT03049449
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas treatment 1 completed NCT02264613
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas treatment 1 / 2 completed NCT01658319
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT04470141
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma No drug interventions treatment 2 unknown_status NCT06089941
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas No drug interventions Not Available Not Available not_yet_recruiting NCT04312841
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab treatment 2 active_not_recruiting NCT02788916
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas No drug interventions Not Available Not Available completed NCT00003196
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma treatment Not Available completed NCT01110135
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma treatment 2 completed NCT06508463
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma treatment 1 recruiting NCT01435863
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) treatment 1 completed NCT06385522
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System No drug interventions treatment 1 not_yet_recruiting NCT01769222
Ipilimumab and Local Radiation for Selected Solid Tumors treatment 1 terminated NCT00038025
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies treatment 2 completed NCT02142530
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL treatment 1 completed NCT06362148
Circulating Tumor DNA in Peripheral T-cell Lymphomas No drug interventions Not Available Not Available recruiting NCT03372057
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) treatment 2 completed NCT01280526
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas treatment 1 / 2 completed NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies supportive_care 2 completed NCT01142674
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma No drug interventions Not Available Not Available completed NCT00458731
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma treatment 1 completed NCT04101331
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides treatment 2 completed NCT03629873
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects treatment 2 unknown_status NCT04447027
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies treatment 1 active_not_recruiting NCT00632827
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) treatment 2 terminated NCT02653976
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) treatment 2 completed NCT04008394
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies No drug interventions treatment 1 unknown_status NCT06433362
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma No drug interventions treatment 2 recruiting NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant treatment 2 completed NCT02013362
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma treatment 1 / 2 completed NCT01129180
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma treatment 1 completed NCT05458180
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma treatment 1 not_yet_recruiting NCT03268889
Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) treatment Not Available unknown_status NCT05900089
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma treatment 1 not_yet_recruiting NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT02168140
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma treatment 1 completed NCT04922567
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma treatment 2 recruiting NCT06468267
RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. treatment 2 recruiting NCT00536601
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors treatment Not Available completed NCT06083701
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study treatment 1 / 2 recruiting NCT02445404
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL treatment 2 unknown_status NCT03952572
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma treatment 3 unknown_status NCT01226472
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 treatment 2 completed NCT04615468
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） No drug interventions treatment 2 unknown_status NCT06244368
GVM±R in Patients With Relapsed or Refractory Aggressive NHL. No drug interventions treatment 2 recruiting NCT02944812
Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma treatment 2 unknown_status NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies treatment 2 completed NCT04083495
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma treatment 2 recruiting NCT01419795
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant treatment 2 terminated NCT00072514
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies treatment 2 completed NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 withdrawn NCT05290155
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies No drug interventions treatment 1 recruiting NCT00364923
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma treatment 2 completed NCT05083208
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma treatment 1 / 2 recruiting NCT03000738
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas No drug interventions Not Available Not Available unknown_status NCT01445535
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas treatment 1 completed